Skip to content
My WebMD Sign In, Sign Up

Brain Cancer Health Center

Font Size

Neuroblastoma Screening (PDQ®): Screening - Health Professional Information [NCI] - Summary of Evidence

Note: Separate PDQ summaries on Neuroblastoma Treatment and Levels of Evidence for Cancer Screening and Prevention Studies are also available.

Intervention

Recommended Related to Brain Cancer

What Is Astrocytoma?

Astrocytoma is a type of brain cancer that usually starts in the cerebrum, the largest part of your brain, but can also show up in the cerebellum (the back of the brain). It’s more common in men than women and most often shows up after age 45. There are several types of astrocytoma, and some grow faster than others. They get their name from astrocytes, the star-shaped cells where they form in the brain. About 50% of primary brain tumors are astrocytomas. Read on to learn more about symptoms,...

Read the What Is Astrocytoma? article > >

Screening, usually at age 6 months, for urine vanillylmandelic acid and homovanillic acid, which are metabolites of the hormones norepinephrine and dopamine.

Benefits

Based on solid evidence, screening for neuroblastoma does not lead to decreased mortality.

Description of the Evidence

  • Study Design: Evidence obtained from nonrandomized controlled trials.
  • Internal Validity: Good.
  • Consistency: Good.
  • Magnitude of Effects on Health Outcomes: No effect on mortality.
  • External Validity: Fair.

Harms

Based on solid evidence, screening infants for neuroblastoma leads to an increase in incidence of early-stage neuroblastoma. There is no concurrent decrease in incidence in screened children of advanced-stage disease, which typically does poorly, or of incidence in children older than 1 year. The cases identified by screening almost exclusively have biologically favorable properties.

Based on solid evidence, screening infants for neuroblastoma results in overdiagnosis (diagnosis of some neuroblastomas detectable by mass screening that would not have been clinically diagnosed later). This leads to unnecessary diagnostic and therapeutic procedures with consequent physical and psychological morbidity, including death from treatment complications.

Description of the Evidence

  • Study Design: Evidence obtained from nonrandomized controlled trials.
  • Internal Validity: Good.
  • Consistency: Good.
  • Magnitude of Effects on Health Outcomes: No effect on mortality. Screening may overdiagnose as many as seven cases per 100,000 infants screened.
  • External Validity: Fair.
1

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

human brain xray
Article
Computed Tomography CT Scan Of The Head
Article
 
Integrative Medicine Cancer Quiz
Article
what is your cancer risk
Health Check
 

Malignant Gliomas
Article
Pets Improve Your Health
SLIDESHOW
 
Headache Emergencies
Video
life after a brain tumor
VIDEO
 

Would you consider trying alternative or complementary therapies?


WebMD Special Sections